Search results
Showing 551 to 600 of 8900 results
This resource is intended to demonstrate how our guidance can be used in the Care Quality Commission (CQC) assessment process.
Mapping NICE guidelines to the CQC's single assessment framework
This NICE resource is intended to demonstrate how our guidance can be used in the Care Quality Commission (CQC) assessment process.
Information and links to key resources that will help you keep your practice up-to-date.
NICE's guidance and advice can help you make the best use of resources and generate cost savings.
NICE is unable to make a recommendation on tislelizumab (Tevimbra) for treating advanced non-small-cell lung cancer after platinum-based chemotherapy in adults. This is because BeiGene withdrew its evidence submission.
Show all sections
Sections for TA1072
Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer (TA1071)
Evidence-based recommendations on atezolizumab (Tecentriq) for the adjuvant treatment of resected non-small-cell lung cancer in adults.
Topical antimicrobial dressings for locally infected leg ulcers: late-stage assessment (HTG751)
Late stage assessment (LSA) guidance on topical antimicrobial dressings for locally infected leg ulcers.
View recommendations for HTG751Show all sections
Home What NICE does Our guidance About technology appraisal guidance {"@context":"http://schema.org","@type":"BreadcrumbList","itemListElement":
We want people from all walks of life to contribute to our work and share their experience, expertise and passion.
Spesolimab for treating generalised pustular psoriasis flares (TA1070)
Evidence-based recommendations on spesolimab (Spevigo) for treating generalised pustular psoriasis flares in adults.
NHS OpenAthens eligibility covers a wide range of those working in health and care, including all staff employed by NHS Trusts. Resources are for users in England only.
Help with registering for your NHS OpenAthens account.
Details of the business expenses incurred by the board and senior management team in delivery of their duties.
Jobs in digital at NICE. Come and join us!
Jobs at NICE. Includes current vacancies, roles, location and salary information.
Our staff really enjoy working with us, thanks to our great package of rewards and benefits.
Check to see if you're entitled to access a range of content purchased by the NHS. If you are eligible, you can register for an OpenAthens account using our online form.
NHS OpenAthens accounts are managed by a network of administrators who can answer questions and offer support to users in England.
NHS OpenAthens is a single sign-on system that provides NHS staff in England with access to a wide range of online, quality healthcare resources.
NICE leads the way in approving breakthrough treatment for multiple myeloma
People in England will become the first in the world to receive belantamab mafodotin for this indication following our recommendation and the UK's Medicines and Healthcare products Regulatory Agency (MHRA) approval earlier this year.
Summaries of the best available evidence for selected medicines that are considered to be of significance to the NHS.
Targeted muscle reinnervation for managing limb amputation pain (HTG750)
Evidence-based recommendations on targeted muscle reinnervation for managing limb amputation pain. This involves attaching nerves that were cut during limb amputation to other nerves in nearby muscles.
This guideline covers when to offer and discuss caesarean birth, procedural aspects of the operation, and care after caesarean birth. It aims to improve the consistency and quality of care for women and pregnant people who are thinking about having a caesarean birth or have had a caesarean birth in the past and are now pregnant again.
Around 3,000 deaths and 5,500 hospital admissions in England caused by chronic heart failure could be prevented each year following our updated draft guideline on medical treatment of the disease.
Learn more about what NICE content is available for reuse by checking our information asset register.
Learn about situations where you cannot use NICE content.
Study NICE and LSE's Executive MSc Healthcare Decision-Making
Study NICE and LSE's Executive MSc Healthcare Decision-Making
Study NICE and LSE's Executive MSc Healthcare Decision-Making
Study NICE and LSE's Executive MSc Healthcare Decision-Making
We’re bringing our guidance together by topic, so that it’s all in one place, clearer to understand and easier to use.
Home Implementing NICE guidance Cost saving, resource planning and audit {"@context":"http://schema.org","@type":"BreadcrumbList","itemListElemen
Our guidance helps you hand over care and ensure people are safely transitioned out of the virtual ward environment.
In virtual wards, people can receive virtual and technology-assisted treatment, assessment, and monitoring.
In virtual wards, patients remain at home to receive hospital-level care. Our guidance can help you determine if patients are suitable for admission to the virtual wards system.
In a virtual ward setting, you make assessments at home to support clinical decision-making. Our guidance can help you give advice by highlighting areas to consider and standards of care.
Efgartigimod for treating antibody-positive generalised myasthenia gravis (TA1069)
Evidence-based recommendations on efgartigimod (Vyvgart) for treating antibody-positive generalised myasthenia gravis in adults.
Show all sections
Evidence-based recommendation on linzagolix (Yselty) for treating symptoms of endometriosis in adults of reproductive age.
Show all sections
Learn more about our updated maternal and child nutrition guideline
Home News Podcasts Learn more about our updated maternal and child nutrition guideline Podcasts 30 May 2025 Listen About this episode We're
Somapacitan for treating growth hormone deficiency in people 3 to 17 years (TA1066)
Evidence-based recommendations on somapacitan (Sogroya) for treating growth hormone deficiency in people 3 to 17 years.
Laparoscopic insertion of an inactive implant for gastro-oesophageal reflux disease (HTG749)
Evidence-based recommendations on laparoscopic insertion of an inactive implant for gastro-oesophageal reflux disease. This involves placing an implant on the outside of the upper part of the stomach wall using keyhole surgery.
View recommendations for HTG749Show all sections
This guideline covers the diagnosis and management of tension-type headache, migraine (including migraine with aura and menstrual-related migraine), cluster headache and medication overuse headache in young people (aged 12 years and older) and adults. It aims to improve the recognition and management of headaches, with more targeted treatment to improve the quality of life for people with headaches, and to reduce unnecessary investigations.
Home News Podcasts Will robotic-assisted surgery change NHS practice forever? Podcasts 30 April 2025 Listen About this episode In this episode
Dr Sarah Byron discusses how NICE is transforming to ensure more digital health technologies are adopted by the NHS.
NICE is unable to make a recommendation on tislelizumab (Tevimbra) for treating unresectable advanced oesophageal squamous cell cancer after platinum-based chemotherapy in adults. This is because BeiGene withdrew its evidence submission.
Show all sections
Sections for TA1068
These are the main stages in the multiple technology appraisal process used before April 2018.
Evidence-based recommendations on nivolumab (Opdivo) plus ipilimumab (Yervoy) for untreated unresectable or metastatic colorectal cancer with high microsatellite instability in adults.
This guideline covers care for women of any age (including girls and young women under 18) who request an abortion. It aims to improve the organisation of services and make them easier for women to access. Detailed recommendations on conducting abortions at different gestational stages are also included, to ensure that women get the safest and most effective care possible.
Over 4,200 people set to benefit after we recommend daily pill to treat rare chronic kidney disease
New treatment sparsentan has been found to slow down the progression of kidney damage, which will change people’s lives for the better.
Our public task statement, which sets out the mandatory functions which NICE is under a legal duty to perform.
Evidence-based recommendations on dostarlimab (Jemperli) with platinum-based chemotherapy for primary advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency in adults.
Show all sections
New weekly treatment option approved for people with haemophilia B
Our final draft guidance published today recommends marstacimab (also called Hympavzi and made by Pfizer) for treating the severe form of blood disorder haemophilia B in people 12 years and over.